Cargando…
Remission of progressive metastatic castration-resistant prostate cancer during abiraterone therapy following unilateral adrenalectomy for a functioning adrenal adenoma
Despite advances and introduction of new therapies in the last decade, metastatic castration-resistant prostate cancer (mCRPC) has a poor prognosis. The development of androgen axis-targeted therapies such as abiraterone acetate, enzalutamide and darolutamide can prolong survival in mCPRC; however,...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535143/ https://www.ncbi.nlm.nih.gov/pubmed/36198431 http://dx.doi.org/10.1136/bcr-2022-251036 |
_version_ | 1784802701831307264 |
---|---|
author | Seale, Katelyn Nazaneen Labriola, Matthew K Jiang, Xiaoyin "Sara" Armstrong, Andrew |
author_facet | Seale, Katelyn Nazaneen Labriola, Matthew K Jiang, Xiaoyin "Sara" Armstrong, Andrew |
author_sort | Seale, Katelyn Nazaneen |
collection | PubMed |
description | Despite advances and introduction of new therapies in the last decade, metastatic castration-resistant prostate cancer (mCRPC) has a poor prognosis. The development of androgen axis-targeted therapies such as abiraterone acetate, enzalutamide and darolutamide can prolong survival in mCPRC; however, resistance remains a barrier to prolonged response, necessitating exploration into resistance mechanisms and locoregional therapies. Here, we describe a patient with mCRPC that was progressing on abiraterone acetate. He was also found to have primary hyperaldosteronism from a functional adrenal adenoma, and thus he had a partial adrenalectomy to remove this tumour. Pathology confirmed an aldosterone-producing adrenal adenoma. After his adrenalectomy, he had a sharp decline in both his PSA (prostate specific antigen) and testosterone levels, and he enjoyed a year-long period of remission after his adrenalectomy. We propose several explanations for his response, the most likely being that his adenoma was producing both aldosterone and androgens. This is a unique case of mCRPC responding to partial adrenalectomy from a functional adrenal adenoma, and it raises insights that warrant further investigation into underlying mechanisms of resistance to androgen-targeted therapies. |
format | Online Article Text |
id | pubmed-9535143 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-95351432022-10-07 Remission of progressive metastatic castration-resistant prostate cancer during abiraterone therapy following unilateral adrenalectomy for a functioning adrenal adenoma Seale, Katelyn Nazaneen Labriola, Matthew K Jiang, Xiaoyin "Sara" Armstrong, Andrew BMJ Case Rep Case Reports: Learning from unexpected outcome (positive or negative) Despite advances and introduction of new therapies in the last decade, metastatic castration-resistant prostate cancer (mCRPC) has a poor prognosis. The development of androgen axis-targeted therapies such as abiraterone acetate, enzalutamide and darolutamide can prolong survival in mCPRC; however, resistance remains a barrier to prolonged response, necessitating exploration into resistance mechanisms and locoregional therapies. Here, we describe a patient with mCRPC that was progressing on abiraterone acetate. He was also found to have primary hyperaldosteronism from a functional adrenal adenoma, and thus he had a partial adrenalectomy to remove this tumour. Pathology confirmed an aldosterone-producing adrenal adenoma. After his adrenalectomy, he had a sharp decline in both his PSA (prostate specific antigen) and testosterone levels, and he enjoyed a year-long period of remission after his adrenalectomy. We propose several explanations for his response, the most likely being that his adenoma was producing both aldosterone and androgens. This is a unique case of mCRPC responding to partial adrenalectomy from a functional adrenal adenoma, and it raises insights that warrant further investigation into underlying mechanisms of resistance to androgen-targeted therapies. BMJ Publishing Group 2022-10-05 /pmc/articles/PMC9535143/ /pubmed/36198431 http://dx.doi.org/10.1136/bcr-2022-251036 Text en © BMJ Publishing Group Limited 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Case Reports: Learning from unexpected outcome (positive or negative) Seale, Katelyn Nazaneen Labriola, Matthew K Jiang, Xiaoyin "Sara" Armstrong, Andrew Remission of progressive metastatic castration-resistant prostate cancer during abiraterone therapy following unilateral adrenalectomy for a functioning adrenal adenoma |
title | Remission of progressive metastatic castration-resistant prostate cancer during abiraterone therapy following unilateral adrenalectomy for a functioning adrenal adenoma |
title_full | Remission of progressive metastatic castration-resistant prostate cancer during abiraterone therapy following unilateral adrenalectomy for a functioning adrenal adenoma |
title_fullStr | Remission of progressive metastatic castration-resistant prostate cancer during abiraterone therapy following unilateral adrenalectomy for a functioning adrenal adenoma |
title_full_unstemmed | Remission of progressive metastatic castration-resistant prostate cancer during abiraterone therapy following unilateral adrenalectomy for a functioning adrenal adenoma |
title_short | Remission of progressive metastatic castration-resistant prostate cancer during abiraterone therapy following unilateral adrenalectomy for a functioning adrenal adenoma |
title_sort | remission of progressive metastatic castration-resistant prostate cancer during abiraterone therapy following unilateral adrenalectomy for a functioning adrenal adenoma |
topic | Case Reports: Learning from unexpected outcome (positive or negative) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535143/ https://www.ncbi.nlm.nih.gov/pubmed/36198431 http://dx.doi.org/10.1136/bcr-2022-251036 |
work_keys_str_mv | AT sealekatelynnazaneen remissionofprogressivemetastaticcastrationresistantprostatecancerduringabirateronetherapyfollowingunilateraladrenalectomyforafunctioningadrenaladenoma AT labriolamatthewk remissionofprogressivemetastaticcastrationresistantprostatecancerduringabirateronetherapyfollowingunilateraladrenalectomyforafunctioningadrenaladenoma AT jiangxiaoyinsara remissionofprogressivemetastaticcastrationresistantprostatecancerduringabirateronetherapyfollowingunilateraladrenalectomyforafunctioningadrenaladenoma AT armstrongandrew remissionofprogressivemetastaticcastrationresistantprostatecancerduringabirateronetherapyfollowingunilateraladrenalectomyforafunctioningadrenaladenoma |